47652 Federal Register / Vol. 86, No. 163 / Thursday, August 26, 2021 / Notices 

Development Plan (IDP) is an important 

step in helping a trainee’s career and 

professional development and is 

standard practice in graduate and 

postdoctoral education. An IDP is an 

effective tool for trainees to think about 

their career goals and skills needed to 

achieve them during their time at the 

NEI. Trainees work together with their 

research mentor to organize and 

summarize their research projects, 

consider career goals, and set training 

goals and expectations, both for the 

mentee and mentor. 

This information collection request is 

to implement an electronic Individual 

Development Plan (eIDP). The data 

collected comes from a detailed 

questionnaire focused on responses to 

professional goals and expectations 

while they are at the NEI. It is expected 

that the trainees will complete the eIDP 

annually and by doing so, it will help 

enhance the effectiveness of their 

training by setting clear goals that can 

be monitored not only by the trainee 

themselves but also by their mentor, the 

Training Director, and their 

Administrative Officer. In addition to 

this eIDP, the system will also 

implement an electronic exit survey. 

The data collected comes from a 

detailed questionnaire focused on 

responses to questions focused on 

trainee mentoring and professional 

experiences at the NEI as well as their 

plans after they depart. It is expected 

that the trainees will complete at the 

end of their tenure and that by doing so, 

the NEI Training Program can learn 

about ways to improve career 

development opportunities for future 

trainees as well as learn more about 

trainee job choices to better advise 

fellows. Additionally, we can use the 

survey to help determine mentor 

effectiveness and help identify problems 

in mentoring at the NEI. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

213. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

time per 

response 

(in hours) 

Total annual 

burden hour 

eIDP (Attachment 1) ......................... Individuals ........................................ 150 1 1 150 

Exit Survey Part 1 (Attachment 2) .... Individuals ........................................ 150 1 5/60 13 

Exit Survey Part 2 (Attachment 3) .... Individuals ........................................ 150 1 20/60 50 

Total ........................................... ........................................................... 150 150 ........................ 213 

Dated: August 19, 2021. 

Cesar E. Perez-Gonzalez, 

Training Director, National Eye Institute, 

National Institutes of Health. 

[FR Doc. 2021–18393 Filed 8–25–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–6: NCI 

Clinical and Translational Cancer Research. 

Date: October 12, 2021. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W240, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Rockville, 

Maryland 20850, 240–276–5122, 

hasan.siddiqui@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–1: NCI 

Clinical and Translational Cancer Research. 

Date: October 28, 2021. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W242, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Zhiqiang Zou, M.D., Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W242, Rockville, 

Maryland 20850, 240–276–6372, zouzhiq@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Metastasis 

Research Network (U54). 

Date: October 28–29, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W238, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Byeong-Chel Lee, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W238, Rockville, Maryland 20850, 

240–276–7755, byeong-chel.lee@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Proteogenomic Tumor Analysis. 

Date: November 3, 2021. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W114, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Jeffrey E. DeClue, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W114, Rockville, Maryland 

20850, 240–276–6371, decluej@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; R03 

Omnibus and R21 Clinical and Translational 

Research. 

Date: November 3, 2021. 

Time: 10:00 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W556, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Kamal Datta, M.D., 

Scientific Review Officer, Program 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 163 / Thursday, August 26, 2021 / Notices 47653 

Coordination and Referral Branch, Division 

of Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W556, Rockville, Maryland 20850, 

240–276–6526, kamal.datta@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Research 

Projects in Cancer Systems Biology (U01). 

Date: November 4, 2021. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W242, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Zhiqiang Zou, M.D., Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W242, Rockville, 

Maryland 20850, 240–276–6372, zouzhiq@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Institutional Training and Education Special 

Emphasis Panel. 

Date: November 4, 2021. 

Time: 1:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W234, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Adriana Stoica, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W234, Rockville, Maryland 20850, 

240–276–6368, Stoicaa2@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 23, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–18399 Filed 8–25–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–[USCG–2021–0042]] 

Revisions to Maritime Security 

Directive 104–6; Guidelines for U.S. 

Vessels Operating in High Risk Waters 

AGENCY: Coast Guard, DHS. 

ACTION: Notice of availability. 

SUMMARY: The Coast Guard announces 

the availability of Revision 8 to 

Maritime Security (MARSEC) Directive 

104–6, which provides guidelines for 

U.S. vessels operating in high-risk 

waters (HRW) where acts of terrorism, 

piracy, and armed robbery against ships 

are prevalent. The directive contains 

security-sensitive information and, 

therefore, cannot be made available to 

the general public. U.S. vessel owners 

and operators who have needed to take 

action under previous versions of 

MARSEC Directive 104–6 should 

immediately contact their local Coast 

Guard Captain of the Port or District 

Commander for a copy of Revision 8. 

This revision contains important 

updates to HRW locations and 

organizational responsibilities regarding 

addressing security risks in those 

waters. 

DATES: MARSEC Directive 104–6 

(Revision 8) has been available since 

August 11, 2021. MARSEC Directive 

104–6 (Revision 7) is no longer valid 

after that date. 

FOR FURTHER INFORMATION CONTACT: For 

information about this document call or 

email LCDR Michael Metz; U.S. Coast 

Guard, Office of Commercial Vessel 

Compliance; telephone 202–372–1236, 

email cvc.uscg@uscg.mil. 

SUPPLEMENTARY INFORMATION: Maritime 

Security (MARSEC) Directive 104–6 

Revision 8 replaces Revision 7, 

previously signed on March 4, 2014. 

The new directive provides direction to 

U.S. flagged vessels operating in High 

Risk Waters (HRW) where acts of 

terrorism, piracy, and armed robbery 

against ships are prevalent. This 

revision reflects a change in 

organizational responsibilities and 

updates the list of regions identified as 

HRW. 

U.S. vessel owners and operators who 

have needed to take action under 

previous versions of MARSEC Directive 

104–6 should immediately contact their 

local Coast Guard Captain of the Port or 

District Commander for a copy of 

Revision 8, which contains important 

updates to the locations of HRW and to 

the guidelines for addressing security 

risks in those waters. The Coast Guard 

advises owners and operators that, 

under Revision 8, they may need to take 

specific actions in accordance with 

MARSEC Directive 104–6 before their 

vessel enters HRW. 

This notice is issued under authority 

of 33 CFR 101.405(a)(2) and 5 U.S.C. 

552(a). 

Dated: August 23, 2021. 

W.R. Arguin, 

Captain, U.S. Coast Guard, Director of 

Inspections and Compliance. 

[FR Doc. 2021–18391 Filed 8–25–21; 8:45 am] 

BILLING CODE 9110–04–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

Revision of Agency Information 

Collection Activity Under OMB Review: 

Baseline Assessment for Security 

Enhancement (BASE) Program 

AGENCY: Transportation Security 

Administration, Homeland Security 

(DHS). 

ACTION: 30-Day notice. 

SUMMARY: This notice announces that 

the Transportation Security 

Administration (TSA) has forwarded the 

Information Collection Request (ICR), 

Office of Management and Budget 

(OMB) control number 1652–0062, 

abstracted below, to OMB for review 

and approval of a revision to the 

currently approved collection under the 

Paperwork Reduction Act (PRA). The 

ICR describes the nature of the 

information collection and its expected 

burden. The collection allows TSA to 

conduct transportation security-related 

assessments during site visits with 

surface transportation security and 

operating officials. 

DATES: Send your comments by 

September 27, 2021. A comment to 

OMB is most effective if OMB receives 

it within 30 days of publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under Review—Open for 

Public Comments’’ and by using the 

find function. 

FOR FURTHER INFORMATION CONTACT: 

Christina A. Walsh, TSA PRA Officer, 

Information Technology (IT), TSA–11, 

Transportation Security Administration, 

6595 Springfield Center Drive, 

Springfield, VA 20598–6011; telephone 

(571) 227–2062; email TSAPRA@

tsa.dhs.gov. 

SUPPLEMENTARY INFORMATION: TSA 

published a Federal Register notice, 

with a 60-day comment period soliciting 

comments, of the following collection of 

information on June 4, 2021, 86 FR 

30065. 


jbell on DSKJLSW7X2PROD with NOTICES